beta
Trial Radar AI

Let's discuss and explore clinical trials with UNICANCER as a lead sponsor or collaborator.

Showing clinical trials for Neoplasms matching location: France.

I can help you find clinical trials in specific locations and provide insights on health conditions and treatments.

With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

107 Results
Top 50 Showing
 
Status (Default)
Not yet Recruiting, Recruiting, Active, Not Recruiting
×
  
Condition
Neoplasms
×
 
Location
France
×
 
Study Title
Status
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation (GENEPSO) NCT03667417
Recruiting
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé) NCT02304809
Active, not recruiting
Chronic Toxicities Related to Treatment in Patients With Localized Cancer (CANTO) NCT01993498
Recruiting
Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence (STEREO-RE-PRO) NCT03438552
Active, not recruiting
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer (OPT-PEMBRO) NCT06606730
Recruiting
Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) NCT05615818
Recruiting
Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk (PRE-ACT-01) NCT07187726
Recruiting
Validation of the European Oncology Quality of Life Toolkit NCT05947903
Not yet recruiting
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA) NCT05973864
Recruiting
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells (AcSé PEMI) NCT06653777
Recruiting
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT-FR) NCT07241273
Not yet recruiting
TARGETed Therapy Drug MONITOring in DIGestive Oncology (TARGETMONITO) NCT05443087
Recruiting
Tracking Triple-negative Breast Cancer Evolution Through Therapy (TRACERX-TNBC) NCT03077776
Active, not recruiting
Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. (TUMOSPEC) NCT03246841
Active, not recruiting
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors NCT02375204
Active, not recruiting
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) NCT02215265
Active, not recruiting
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers (NEOREM) NCT07262489
Recruiting
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test (CIRCULATEIII) NCT07340567
Not yet recruiting
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG) NCT03774732
Active, not recruiting
Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers (CROCOBIL) NCT07437287
Not yet recruiting
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer (ALTER) NCT07151586
Not yet recruiting
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme (FUDOSE) NCT06475352
Recruiting
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. (AcSé HER2) NCT07192068
Recruiting
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) NCT02867033
Active, not recruiting
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18) NCT00967863
Active, not recruiting
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases (COLIBRI-GI) NCT07359456
Not yet recruiting
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients (SEVILLA) NCT06529718
Recruiting
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) NCT06333314
Recruiting
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT) NCT04747054
Recruiting
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour (L-UteCIN) NCT06524583
Recruiting
Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only (RC-102) NCT06867705
Recruiting
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER) NCT04985266
Recruiting
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (OPTIMA-YOUNG) NCT07106632
Not yet recruiting
Reproductive Health in Breast Cancer Survivor (ISIS) NCT06756802
Active, not recruiting
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (AMBRE) NCT04158362
Active, not recruiting
Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk. (MyPREV) NCT07120087
Recruiting
Patient's Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast Cancer (CARTE) NCT05058196
Active, not recruiting
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases (STEREO-OS) NCT03143322
Active, not recruiting
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib (NoLEEta) NCT07237256
Recruiting
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC) NCT03848052
Recruiting
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) NCT02947685
Active, not recruitingResults Posted
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. (HEROES) NCT06450314
Recruiting
Phase III Radium 223 mCRPC-PEACE III NCT02194842
Active, not recruiting
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers (OASIS) NCT07259226
Recruiting
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk (LESS) NCT05297617
Recruiting
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (CARLHA-2) NCT04181203
Active, not recruiting
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE) NCT05552001
Recruiting
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (ASTER 70s) NCT01564056
Active, not recruiting
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN) NCT03799835
Active, not recruiting
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors NCT05974774
Recruiting